Despite the major societal burden of p95HER2-expressing breast cancers and the increased aggressiveness of these cancers compared to those expressing the full-length HER2 variant3,4, little is known regarding the functional differences between these two receptor variants. Here, ERBB2 is linked to breast carcinoma.